The pharmaceutical giant is strengthening its respiratory drug portfolio ahead of losing patent protection for Keytruda, its blockbuster cancer treatment.
The pharmaceutical giant is strengthening its respiratory drug portfolio ahead of losing patent protection for Keytruda, its blockbuster cancer treatment.
Merck has agreed to purchase biotechnology company Cidara Therapeutics for $9.2 billion, marking the latest in a series of strategic acquisitions designed to fortify the pharmaceutical giant’s pipeline before it loses exclusive rights to its most profitable drug. The deal represents a significant premium for Cidara shareholders and underscores the urgency with which major drugmakers are seeking new revenue sources.
The New Jersey based pharmaceutical company announced Friday it would pay $221.50 per share for the San Diego biotech firm, a price that more than doubles Cidara’s closing stock price of $105.99 from the previous day. The substantial premium reflects both the value Merck places on Cidara’s assets and the competitive landscape for promising drug candidates in the respiratory disease space.
A strategic bet on flu prevention
At the heart of the acquisition lies CD388, Cidara’s leading drug candidate that has captured Merck’s attention and investment. The antiviral agent is currently advancing through Phase 3 clinical studies, where researchers are evaluating its effectiveness in preventing influenza infections among individuals facing elevated risk of serious flu complications. Success in these trials could position the drug as a significant commercial product in a market where prevention options remain limited.
The transaction is expected to finalize during the first quarter of 2026, giving both companies time to navigate regulatory approvals and integration planning. For Cidara shareholders, the deal offers immediate and substantial returns, with shares surging to $215.50 in premarket trading following the announcement, more than doubling their value overnight.
Building a respiratory powerhouse
This acquisition follows closely on the heels of another major purchase in the respiratory disease arena. Just last month, Merck completed a roughly $10 billion acquisition of Verona Pharma, gaining access to Ohtuvayre, a treatment for chronic obstructive pulmonary disease. The back to back deals signal a clear strategic direction as Merck positions itself as a leader in respiratory therapeutics.
Chief Executive Rob Davis has characterized CD388 as a potentially important growth driver for the coming decade, expressing confidence that the acquisition will deliver meaningful value to shareholders. His optimism reflects broader industry trends showing increased investment in respiratory diseases, particularly following heightened awareness of airborne illness prevention in recent years.
The Keytruda challenge
The aggressive acquisition strategy stems from a looming financial challenge that keeps pharmaceutical executives awake at night. Merck faces a 2028 patent cliff for Keytruda, its enormously successful cancer immunotherapy that generated nearly $29.5 billion in sales last year alone. When patent protection expires, generic competitors will enter the market, inevitably eroding Merck’s revenue from what has been its most lucrative product.
Davis has been transparent about the company’s approach to this challenge, previously indicating that Merck maintains an appetite for additional deals and views acquisitions valued up to $15 billion as an ideal size range. This strategic framework suggests shareholders should anticipate more transactions as the company races to build a diversified portfolio capable of offsetting the inevitable Keytruda revenue decline.
Industry consolidation continues
The Cidara deal fits within a broader pattern of consolidation sweeping through the pharmaceutical and biotechnology sectors. Large drugmakers increasingly rely on acquisitions to replenish their pipelines, finding it more efficient to purchase promising candidates in late stage development than to invest the time and resources required to develop new drugs internally from scratch.
For smaller biotech companies like Cidara, these dynamics create opportunities to deliver returns to investors through strategic sales rather than navigating the expensive and risky path to commercialization independently. The arrangement benefits both parties, with established pharmaceutical companies gaining immediate access to advanced candidates while biotech firms receive the capital and infrastructure support of industry giants.
As Merck moves forward with integrating Cidara’s operations and advancing CD388 through final clinical trials, the pharmaceutical industry will watch closely to see whether this acquisition strategy successfully prepares the company for life after Keytruda dominance.
